Immunohistochemical expression of HER-2/neu receptors in gastric carcinoma

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorIshaky, Elia A
dc.contributor.authorEl-Sharkawy, Sonia L
dc.contributor.authorAyob, Menar M
dc.contributor.authorSharaf, Hafiza A
dc.contributor.authorBakeer, Rofanda M
dc.date.accessioned2019-10-27T10:30:41Z
dc.date.available2019-10-27T10:30:41Z
dc.date.issued07/01/2017
dc.description.abstractBackground/aim Gastric carcinoma is the fourth most commonly diagnosed cancer and the second most common cause of cancer-related death. It is associated with patient morbidity and mortality worldwide. Adenocarcinomas represent 90% of gastric carcinoma cases and are classified into intestinal and diffuse types. Human epidermal growth factor receptor 2 (HER-2)/neu overexpression is a predictor of poor prognosis. This study aimed to evaluate HER-2/neu expression in gastric carcinomas and to correlate its expression with clinicopathological parameters and other prognostic factors.en_US
dc.identifier.citationBerlth B, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. World J Gastroenterol 2014; 20:5679–5684. Back to cited text no. 1 2. Bing HB, El Hajj N, Sittler S, Lammert N, Barnes R, Ehrig AM. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol 2012; 3:251–261. Back to cited text no. 2 3. Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer 2008; 44:2397–2403. Back to cited text no. 3 4. Qin J, Liu M, Ding Q, Ji X, Hao Y, Wu X et al. The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells. Mol Cell Biochem 2014; 395:99–107. Back to cited text no. 4 5. González CA, Sala N, Rokkas T. Gastric cancer: epidemiologic aspects. Helicobacter. 2013; 18:34–38. Back to cited text no. 5 6. Nomura A, Grove JS, Stemmermann GN, Severson RK. Cigarette smoking and stomach cancer. Cancer Res 1990; 50:7084–7090. Back to cited text no. 6 7. Trédaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A. Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer 1997; 72:565–573. Back to cited text no. 7 8. Jakszyn P, González CA. Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence. World J Gastroenterol 2006; 12:4296–4303. Back to cited text no. 8 9. Amelot MEA, Avendaño M. Human carcinogenesis and bracken fern: a review of the evidence. Curr Med Chem 2002; 9:675–686. Back to cited text no. 9 10. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H et al. Hereditary diffuse gastric cancer syndrome CDH1 mutations and beyond. JAMA Oncol 2015; 1:23–32. Back to cited text no. 10 11. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37:54–66. Back to cited text no. 11 12. Laurén T. The two histologic main types of gastric carcinoma. Acta Pathol Microbiol Scand 1965; 64:31–49. Back to cited text no. 12 13. Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer 2001; 84:400–405. Back to cited text no. 13 14. Yasui W, Sentani K, Motoshita J, Nakayama H. Molecular pathobiology of gastric cancer. Scand J Surg 2006; 95:225–231. Back to cited text no. 14 15. Kitaura K, Chone Y, Satake N, Akagi A, Ohnishi T, Suzuki Y et al. Role of copper accumulation in spontaneous renal carcinogenesis in Long-Evans Cinnamon rats. Jpn J Cancer Res 1999; 90:385–392. Back to cited text no. 15 16. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232:1644–1646. Back to cited text no. 16 17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177–182. Back to cited text no. 17 18. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 2015; 34:157–164. Back to cited text no. 18 19. Machado LFA, Neto CM. HER2 testing in gastric cancer: an update. World J Gastroenterol 2016; 22:4619–4625. Back to cited text no. 19 20. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Liorca FP et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012; 25:637–650. Back to cited text no. 20 21. James LA, Douglas BE, Christopher W, Cecilia FP. Pathology and natural history of gastric cancer [Chapter 2]. In: XX X, editors. Gastrointestinal oncology. XX: XX; 2004. pp. 281–294. Back to cited text no. 21 22. Parkin DM. International variation. Oncogene 2004; 23:6329–6340. Back to cited text no. 22 23. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 200. Int J Cancer 2010; 127:2893–2917. Back to cited text no. 23 24. Wagner AD, Grothe W, Haeting J. Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903–2909. Back to cited text no. 24 25. Cutsem EV, Kang Y, Chung H, Shen L, Sawaki A, Lordick F et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27:18 s (suppl; abstr LBA 4509). Back to cited text no. 25 26. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:637–650. Back to cited text no. 26 27. Ghosh P, Chakrabarti I, Bhowmick S, Gangopadhyay M, Sinha MGM, Bhattacharya S. Overexpression of Her2/Neu in gastric carcinoma: association with histological type, tumor grade and H. pylori infection. Ann Pathol Lab Med 2016; 3:184–188. Back to cited text no. 27 28. García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P, García-Muñiz JL. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003; 10:234–241. Back to cited text no. 28 29. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51:1371–1379. Back to cited text no. 29 30. Raziee HR, Taghizadeh KA, Ghaffarzadegan K, Taghi SM, Ghavamnasiri MR. HER-2/neu expression in resectable gastric cancer and its relationship with histopathologic subtype, grade, and stage. Iran J Basic Med Sci 2007; 10:139–145. Back to cited text no. 30 31. Pinto-de-Sousa J, David L, Almeida R. C-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002; 10:247–256. Back to cited text no. 31 32. Kuraoka K, Matsumura S, Hamai Y, Nakachi K, Imai K, Matsusaki K et al. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. Cancer 2003; 107:593–596. Back to cited text no. 32 33. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham D. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92:1991–1998. Back to cited text no. 33 34. Tufan NLS, Bir F, Demirkan NC. Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients. World J Gastroenterol 2006; 12:3283–3287. Back to cited text no. 34 35. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19:1523–1529. Back to cited text no. 35 36. Laboissiere RS, Buzelin MA, Balabram D, Brot MD, Nunes CB, Rocha RM et al. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. BMC Gastroenterol 2015; 15:157–162. Back to cited text no. 36 37. Son HS, Shin YM, Park KK, Seo KW, Yoon KY, Jang HK et al. Correlation between HER2 overexpression and clinicopathological characteristics in gastric cancer patients who have undergone curative resection. J Gastric Cancer 2014; 14:180–186. Back to cited text no. 37 38. Dewan K, Madan R, Sengupta P. Correlation of Lauren’s histological type and expression of E-cadherin and HER-2/neu in gastric adenocarcinoma. Internet J Pathol Lab Med 2016; 2:1–5. Back to cited text no. 38 39. Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer − a systematic analysis of data from the literature. J Cancer 2012; 3:137–144. Back to cited text no. 39 40. Ross JS, McKenna B. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19:554–568. Back to cited text no. 40en_US
dc.identifier.doihttps://doi.org/10.4103/jasmr.jasmr_4_17
dc.identifier.otherhttps://doi.org/10.4103/jasmr.jasmr_4_17
dc.identifier.urihttp://new.asmr.eg.net/article.asp?issn=1687-4293;year=2017;volume=12;issue=1;spage=13;epage=18;aulast=Ishaky
dc.language.isoen_USen_US
dc.publisherMedknow Publicationsen_US
dc.relation.ispartofseriesJournal of The Arab Society for Medical Research;Volume : 12 | Issue : 1 | Page : 13-18
dc.subjectgastric carcinomaen_US
dc.subjectHER-2/neuen_US
dc.subjectimmunohistochemistryen_US
dc.titleImmunohistochemical expression of HER-2/neu receptors in gastric carcinomaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download

Collections

Faculty Of Dentistry Research Paper